CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Claritev beats Q3 revenue estimates, raises forecast

By Reuters News


Overview

  • Healthcare data platform's Q3 revenue grew 9.1% yr/yr, beating analyst expectations

  • Adjusted EBITDA for Q3 rose 4.4%, beating analyst expectations

  • Company raised full-year 2026 revenue and adjusted EBITDA guidance


Outlook

  • Claritev raises 2026 revenue guidance to $1.038 bln-$1.043 bln

  • Company lifts 2026 adjusted EBITDA forecast to $625 mln-$630 mln

  • Company provides preliminary 2027 revenue outlook of $1.1 bln


Result Drivers

  • BROAD-BASED GROWTH - Co cited growth across solutions and industry verticals, supported by increased adoption of AI in workflows, per CEO Travis Dalton

  • DIVERSIFICATION STRATEGY - Co attributed results to its diversification strategy, which management said is delivering strong financial results and accelerating growth

  • PRODUCT EXPANSION - Co highlighted expanded offerings such as Transparency-Based Pricing and Healthcare Intelligence platform as drivers of client engagement


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$268.31 mln

$256.13 mln (3 Analysts)

Q3 Loss Per Share

$3.64

Q3 Net Loss

$61.79 mln

Q3 Adjusted EBITDA

Beat

$162 mln

$155.83 mln (4 Analysts)

Q3 Operating Income

Miss

$20.63 mln

$57.33 mln (3 Analysts)

Q3 Pretax Loss

Beat

$80.03 mln

$86.46 mln (3 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the business support services peer group is "buy"

  • Wall Street's median 12-month price target for Claritev Corp is $43.00, about 89.3% above its November 6 closing price of $22.71


Reuters Recommended Reads

  • Nov 6 - Humana lifts annual profit forecast as medical costs ease

  • Nov 6 - UK's Immunocore Q3 loss misses estimates on higher R&D spending

  • Nov 6 - Canada's Docebo Q3 revenue beats estimates on subscription growth


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.